September 15, 2026
The Limners and Bards Limited (LAB)
Unaudited financials for the nine months ended July 31, 2026:
The Limners and Bards Limited (LAB) for the nine months ended July 31, 2026, reported a 15% decrease in Operating revenue totaling $618.49 million compared to $727.35 million in the corresponding period last year. Operating revenue for the third quarter had a 5% increase to close at $280.71 million compared to $267.14 million for the comparable quarter of 2025.
Year to date, the cost of operating revenue amounted to $413.09 million (2025: $450.12 million), this represents a decrease of 8% year over year. Consequently, gross profit decreased by 26% to $205.40 million compared to $277.23 million for the nine months ended July 31, 2025. The company booked gross profit of $78.98 million for the third quarter versus $101.77 million reported for the similar quarter of 2025.
Selling and distribution expenses increased by 325% to close at $16.56 million (2025: $3.89 million), while administrative expenses decreased by 8% from $228.90 million in 2025 to $211.23 million in the period under review. As a result, total operating expenses for the nine months ended July 31, 2026, amounted to $227.79 million, a 2% decrease relative to $232.80 million reported in 2025.
Loss before net finance cost and taxation for the nine months ended July 31, 2026, amounted to $19.82 million, relative to a profit of $43.71 million reported in 2025. Loss before net finance cost and taxation for the third quarter amounted to $5.53 million (2025: profit of $22.33 million). Finance income totaled $10.67 million (2025: $13.08 million) while finance costs were $11.02 million (2025: $7.99 million), resulting in a net finance cost of $0.35 million (2025: net finance income of $5.10 million).
Loss before taxation for the nine months ended July 31, 2026, amounted to $20.05 million, relative to a profit of $48.78 million reported in 2025. Loss before taxation for the third quarter amounted to $3.72 million (2025: profit of $24.78 million).
A tax credit of $1.88 million was recognized for the nine months (2025: charge of $6.52 million). As a result, net loss for the nine months amounted to $18.17 million, relative to a net profit of $42.26 million reported in 2025. For the third quarter, Net loss was $4.68 million (2025: profit of $21.66 million).
Consequently, Loss Per Share for the nine months amounted to $0.02 (2025: EPS: $0.04), while Loss Per Share for the quarter totaled $0.005 (2025: EPS: $0.02). The twelve-month trailing LPS was $0.02, and the number of shares used in these calculations was 945,690,252.
Notably, LAB’s stock price closed the trading period on September 14, 2026 at a price of $1.01.
Balance Sheet Highlights
The company’s assets totalled $1.11 billion (2025: $1.10 billion). The movement in total assets was mainly attributed to a 6% increase in ‘Accounts receivable’ amounting to $378.86 million (2025: $357.04 million) and a 136% increase in ‘Due from related parties’ to $36.92 million (2025: $15.66 million), partly offset by a 13% decrease in ‘Cash and cash equivalents’ amounting to $284.07 million (2025: $326.64 million).
Shareholders’ equity was $643.83 million (2025: $680.81 million), representing a book value per share of $0.68 (2025: $0.72).
Disclaimer:
Analyst Certification – The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer(s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this research report.
Company Disclosure – The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.
